Global H3N2 Infection Drugs Market - 2024-2031

Global H3N2 Infection Drugs Market - 2024-2031

The global H3N2 infection drugs market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031 growing with a CAGR of YY% during the forecast period 2024-2031.

The H3N2 infection is infectious and usually spreads effectively from one individual to another through respiratory droplets. H3N2 viruses generally infect birds, humans, and pigs and H3N2 virus infection usually lasts between five and seven days but can also cause a severe cough that lasts up to three weeks. H3n2 infection can be prevented by covering the nose and mouth with a tissue while coughing or sneezing.

The global H3N2 infection drugs market has grown significantly in recent years due to the adoption of antiviral medications such as the drugs like oseltamivir, baloxavir, and peramivir can be taken and these antiviral medications are administered within 48 hours of developing flu symptoms.

Market Dynamics: Drivers

Increasing Product Launches and Rising FDA Approvals for H3N2 Infection Drugs

The demand for the global H3N2 infection drugs market is driven by multiple factors. One of the key factors is the increasing product launches and rising FDA approvals for H3N2 infection treatment.

H3N2 is a subtype of influenza virus type A that causes respiratory illness in humans. Major players in the market are more focused on the development of treatment for H3N2 infections and product launches and approvals would drive this market growth. These effective product launches help to transform research discoveries into new treatments and improve care for millions of people with H3N2 infection.

For instance, in July 2023, Integrated DNA Technologies (IDT) launched a new next-generation sequencing (NGS) solution called the xGen Respiratory Virus Amplicon Panel with 98.7% total genomic coverage of viral respiratory variants Respiratory Syncytial Virus (RSV) A, RSV B, Influenza A H1N1, Influenza A H3N2, Influenza B, and SARS-CoV-2. This configured single panel is designed to monitor the evolution and spread of these six viruses.

Also, in May 2023, Hologic Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. This assay is a molecular diagnostic test that detects and differentiates four of the most prevalent respiratory viruses that can exhibit similar clinical symptoms like severe acute respiratory syndrome (SARS-CoV-2), influenza A, influenza B, and respiratory syncytial virus (RSV).

Restraints

Factors such as antiviral drug resistance, complications associated with the treatment of drugs, limited availability of effective vaccines, high cost of the treatment, and lack of awareness among individuals are expected to hamper the market.

Segment Analysis

The global H3N2 infection drugs market is segmented based on drug type, route of administration, distribution channel, and region.

The vaccines accounted for approximately 54.4% of the global H3N2 infection drugs share

The vaccines segment is expected to hold the largest market share over the forecast period. Vaccines play a crucial role in preventing influenza infections, including those caused by H3N2. Seasonal flu vaccines are typically developed to target the strains of influenza virus expected to be most prevalent in a given flu season. Vaccine formulations often include strains of influenza A (including H3N2) and influenza B viruses.

Moreover, key players in the industry launching new products for the H3N2 infection drugs would propel this segment's growth. For instance, in October 203, Mylab, Serum Institute successfully launch India’s first nasal vaccine NASOVAC S4 for Influenza. The vaccine includes two types of influenza type A strain (A/H1N1 and H3N2) and two influenza type B virus strains.

The rising clinical trials of vaccines globally have contributed to the growing demand for H3N2 infection treatment. According to clinicalTrials.gov, in July 2023, the National Institute of Allergy and Infectious Diseases (NIAID) conducted a clinical trial on the Safety and Immunogenicity of One or Two Doses of the Sing2016 M2SR H3N2 Influenza Vaccine.

This trial aims to assess the safety, tolerability, and immunogenicity of one and two doses of Sing2016 M2SR H3N2 influenza vaccine (manufactured by FluGen) administered intranasally in seven cohorts of children. Also, to assess the safety and tolerability of one and two administrations of the Sing2016 M2SR H3N2 influenza vaccine at 10^7, 10^8, or 10^9 TCID50 delivered intranasally to healthy participants of 6 months to 17 years of age.

Geographical Analysis

North America accounted for approximately 43.3% of the global H3N2 infection drugs market share

North America region is expected to hold the largest market share over the forecast period owing to factors such as the FDA approvals for H3N2 treatment drugs, and rising research and developments in H3N2 infection treatment.

Moreover, the increasing prevalence of influenza infection in the U.S. would propel this market growth. According to the CDC report in June 2023, estimates that there have been at least 35 million illnesses, 390,000 hospitalizations, and 25,000 deaths from flu so far this season.

In addition, a major key player presence, an advanced healthcare system, a rising number of clinical trials, and ongoing research studies in the treatment of H3n2 infections would drive this market growth. For instance, in February 2023, Moderna, Inc. announced interim results from its pivotal Phase 3 safety and immunogenicity trial of mRNA-1010 (P301), an mRNA-based seasonal influenza (flu) vaccine candidate, in adults.

The Phase 3 randomized trial was designed to evaluate the safety and immunogenicity of mRNA-1010 in adults 18 years and older in the Southern Hemisphere. mRNA-1010 encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) to prevent influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages.

Market segmentation

By Drug Type
• Oseltamivir
• Peramivir
• Baloxavir
• Zanamivir
• Vaccines

By Route of Administration
• Oral
• Parenteral
• Others

By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the H3N2 infection drugs market include GlaxoSmithKline Pharmaceuticals, Genentech Inc., Jiangsu Sinopep Biopharmaceuticals, Lupin Ltd., BioCryst Pharmaceuticals, F. Hoffmann-La Roche, Huateng Pharma, Tocris Bioscience, Upsher-Smith Laboratories, Alembic Pharmaceuticals among others.

Key Developments

In May 2023, Clover Biopharmaceuticals Ltd. announced that it had established a commercial partnership with Keyuan Xinhai (Beijing) Medical Products Trading Co. Ltd. (Kyuan Trade) for the commercial launch of AdimFlu-S (QIS) which is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China.

In April 2023, Molbio Diagnostics launched the Truenat H3N2/H1N1 for differential diagnosis of the H3N2 and H1N1 virus. The test is approved by the Central Drugs Standard (CDSCO). Truenat H3N2/H1N1 is the first point-of-care real-time PCR test that aids in the confirmatory diagnosis of influenza infections.

In March 2023, Virax Biolabs Group Limited announced that it has agreed to the distribution of an Avian Influenza A Virus (AIV) real-time PCR test kit. The test kit is for the detection and differentiation of ribonucleic acid from the Avian Influenza A Virus and the H3, H5, H7, and H9 subtypes.

In February 2021, BioCryst announced FDA approval of a supplemental new drug application for RAPIVAB expanding the patient population to include children six months and older. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza.

Why Purchase the Report?
• To visualize the global H3N2 infection drugs market segmentation based on drug type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the global H3N2 infection drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global H3N2 infection drugs market report would provide approximately 62 tables, 56 figures, and 182 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies